We're building agents for autonomous science. Closed-loop, faster iterations, more discovery, less time. Massive human scientist + AI scientist collaboration.
Gene therapies can be delivered in a protein shell called a capsid. Mythos 5.2 found a new way to predict a whole capsid’s structure.
In our tests, it accurately modeled 28 of the 34 capsids it attempted. Biologists could use it to design capsids faster and more cheaply.
I’m actively looking to match ambitious scientists with funding.
Through some combination of my writing, podcasts, in-person events, scientific research and other activities that my friend @markwbudde would call “hypernetworking,” I’ve managed to meet a lot of wealthy individuals interested in funding ambitious scientists. I’ve had my own work funded this way, and though it’s not sustainable enough to replace the work of larger funding bodies of the NIH, for the right kind of person it is just what they need.
I am writing this post because I am helping one of these groups – Fulcrum Science – find projects worth giving money to.
While I’m pretty flexible, I’m particularly interested in hearing from people who are actively working on open sourced LLMs for frontier biology.
Plenty of groups have shown what is possible with frontier, closed-source LLMs. I’ve also seen it in my own work (which I hope to talk about soon). I also think that the absolute frontier of intelligence isn’t required to do interesting things in science.
I’d like to help match an existing lab – academic or industry – with a decent sum of funding to showcase what open sourced models can do in biology.
Pitch me what you’d do.
Please note, I am not looking to hear about any projects that involve Claude or ChatGPT for any reasoning, experimental analysis, or embodied automation stuff. Open source only!
I’m also open to hearing about other things within biology. If you have an idea you have struggled to get funded, and you have a good reason for me to believe you, please reach out.
My email is eryneym [at] https://t.co/LFSC13FgpH. You can also DM me on Twitter.
Been comparing notes with researchers at labs and data vendors, The new data money at frontier labs is going off-screen. Coding data they can mostly make in-house now. Wet-lab runs, robot hours and a real company's inbox they still have to buy
Anthropic alone paid data vendors $757M in the first 9 months of this year. Here's where it's going:
1/Bio is the hardest to fake
Anthropic built its own wet lab and bought Coefficient Bio for ~$400M in stock
OpenAI ran GPT-5 through 36,000 experiments in Ginkgo's cloud lab, and got 173 scientists to write a bio benchmark. Best model: 36%
What they're really buying is bench time
2/Robots are growing fastest
OpenAI reportedly has ~100 contract teleoperators working in shifts around the clock
@xdofai sells to 20 customers, several of them frontier labs. Mecka hit a $100M run rate in June
video is easy now. Touch and force are the gap
3/Then the white-collar stuff
@HalluminateAI builds PE due diligence environments for 4 of the top 5 US closed labs. Best model gets 51%
Google paid $10M for bankrupt Spirit Airlines' emails and Teams messages, and outbid Mercor
A dead company's Slack has a price now
4/Even evals turned into a purchase. Anthropic and Accenture each plan $1B+ over 5 years for evaluators embedded at Anthropic
So the scarce thing is access: a bench, a robot, a real company's history
A major milestone for Chemogenetics. DREADD technology demonstrates therapeutic efficacy in humans.
A new study published today in NEJM demonstrates preliminary safety and therapeutic benefit from DREADD-based chemogenetic treatment of refractory epilepsy, marking an extraordinary milestone for neuroscience and precision medicine.
https://t.co/TZOYgSY7dZ
The approach combines targeted AAV gene delivery at the epileptogenic locus with very low, subthreshold doses of clozapine to activate engineered DREADD receptors and modulate neuronal activity.
Congratulations to Bryan Roth, whose pioneering discovery of DREADDs made this field possible, and to the investigators of the NEJM study for bringing this technology to patients.
This achievement has a particularly meaningful connection to our work published in Science Magazine in 2017.
https://t.co/rWWUuY65Nr
We showed that clozapine, rather than CNO itself, is the active mediator of DREADD activation in vivo and proposed that subthreshold doses of clozapine could be used to activate DREADDs in humans, anticipating a practical path toward clinical translation.
At the time, many in the scientific community viewed these findings primarily as relevant to the design of preclinical DREADD experiments. We saw a much broader opportunity, translating Chemogenetics into human therapeutics. Nearly a decade later, that vision is now becoming a reality.
Our 2017 study was supported by the research funding through the National Institutes of Health (NIH) and The National Institute on Drug Abuse (NIDA), a prime example of how fundamental basic research can ultimately enable transformative clinical applications.
This is an exciting beginning, but larger, well-controlled studies are essential to establish the magnitude and durability of therapeutic benefit and long-term safety.
Chemogenetics is moving beyond an experimental neuroscience tool toward a potentially transformative neuroscience platform. We are only beginning to realize its potential.